Literature DB >> 21824836

The effect of propofol-remifentanil anesthesia on selected seizure quality indices in electroconvulsive therapy.

Stephen H Dinwiddie1, David B Glick2, Morris B Goldman3.   

Abstract

BACKGROUND: Use of a short-acting opiate to potentiate anesthetic induction agents has been shown to increase seizure duration in electroconvulsive therapy (ECT), but little is known of the effect of this combination on indices of seizure quality.
OBJECTIVE: To determine whether anesthetic modality affects commonly provided indices of seizure quality.
METHODS: Twenty-five subjects were given propofol 2 mg/kg body weight for their first ECT session, at which time seizure threshold was titrated. Subjects thereafter alternated between that anesthetic regimen or propofol 0.5 mg/kg plus remifentanil 1 mcg/kg. Linear mixed models with random subject effect, adjusting for electrode placement, electrical charge, and number of treatments, were fit to estimate effect of anesthesia on seizure duration and several standard seizure quality indices (average seizure energy, time to peak electroencephalography (EEG) power, maximum sustained power, interhemispheric coherence, early and midictal EEG amplitude, and maximum sustained interhemispheric EEG coherence).
RESULTS: Propofol-remifentanil anesthesia significantly lengthened seizure duration and was associated with longer time to reach maximal EEG power and coherence as well as maximal degree of interhemispheric EEG coherence. No effect was seen on early ictal amplitude or average seizure energy index.
CONCLUSIONS: Propofol-remifentanil anesthesia prolongs seizure duration and has a significant effect on some, but not all, measures of seizure quality. This effect may be of some benefit in cases where adequate seizures are otherwise difficult to elicit. Varying anesthetic technique may allow more precise investigation of the relationships between and relative impacts of commonly used seizure quality indices on clinical outcomes and ECT-related cognitive side effects.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824836     DOI: 10.1016/j.brs.2011.06.008

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


  6 in total

1.  Central-Positive Complexes: A Novel Characterization of Ictal Markers Induced During Electroconvulsive Therapy.

Authors:  R Edward Hogan; Emma R Trammel; Nuri B Farber; Michael S Avidan; Ben Julian A Palanca
Journal:  J ECT       Date:  2019-12       Impact factor: 3.635

Review 2.  [Anesthesia for electroconvulsive therapy].

Authors:  U Grundmann; S O Schneider
Journal:  Anaesthesist       Date:  2013-04       Impact factor: 1.041

3.  Does remifentanil improve ECT seizure quality?

Authors:  Verònica Gálvez; Phern-Chern Tor; Adriana Bassa; Dusan Hadzi-Pavlovic; Ross MacPherson; Mincho Marroquin-Harris; Colleen K Loo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-01       Impact factor: 5.270

Review 4.  Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yoshiteru Takekita; Taro Suwa; Naotaka Sunada; Hirotsugu Kawashima; Chiara Fabbri; Masaki Kato; Aran Tajika; Toshihiko Kinoshita; Toshi A Furukawa; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-01-28       Impact factor: 5.270

5.  Effects of Propofol and Propofol-Remifentanil Combinations on Haemodynamics, Seizure Duration and Recovery during Electroconvulsive Therapy.

Authors:  Canan İkiz; Ferim Günenç; Leyla İyilikçi; Şule Özbilgin; Hülya Ellidokuz; Can Cimilli; Zehra Mermi; Erol Gökel
Journal:  Turk J Anaesthesiol Reanim       Date:  2020-12-16

6.  Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol.

Authors:  Ben J A Palanca; Hannah R Maybrier; Angela M Mickle; Nuri B Farber; R Edward Hogan; Emma R Trammel; J Wylie Spencer; Donald D Bohnenkamp; Troy S Wildes; ShiNung Ching; Eric Lenze; Mathias Basner; Max B Kelz; Michael S Avidan
Journal:  Front Psychiatry       Date:  2018-05-14       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.